IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
Krueger J, Eyerich K, Kuchroo V, Ritchlin C, Abreu M, Elloso M, Fourie A, Fakharzadeh S, Sherlock J, Yang Y, J. D, McInnes I. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Frontiers In Immunology 2024, 15: 1331217. PMID: 38686385, PMCID: PMC11056518, DOI: 10.3389/fimmu.2024.1331217.Peer-Reviewed Original ResearchConceptsImmune-mediated inflammatory diseasesIL-23 inhibitionIL-23Anti-IL-23 therapyOptimal identification of patientsTreat immune-mediated inflammatory diseasesIL-12 cytokine family memberInterleukin (IL)-23Identification of patientsIL-23 signalingCytokine family membersInflammatory bowel diseaseMolecular ontologiesRegulatory cytokinesIL-12Psoriatic arthritisInflammatory diseasesBowel diseaseDiseaseTherapyFamily membersBiologyLAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
Joller N, Anderson A, Kuchroo V. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity 2024, 57: 206-222. PMID: 38354701, PMCID: PMC10919259, DOI: 10.1016/j.immuni.2024.01.010.Peer-Reviewed Original ResearchConceptsLAG-3Tim-3Immune cellsRestraining T-cell responsesImmune checkpoint receptorsT cell responsesRegulation of immune cellsImmune cell typesApplication of therapyPotential tissue toxicityCheckpoint receptorsTissue toxicityT cellsClinical developmentImmune regulationTIGITCell responsesReceptorsCell typesClinicCellsTherapy